Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Keywords

Docetaxel, Estramustine, Mitoxantrone, Medicine, Prednisone

References

• Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.Daniel P. Petrylak, Robert B. MacArthur, Jacqueline M. O’Connor — 1999
• Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.Daniel P. Petrylak, Robert B. MacArthur, John F. O’Connor — 1999
• Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.Philip W. Kantoff, Susan Halabi, Mark R. Conaway — 1999
• Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.Gary R. Hudes, Lawrence H. Einhorn, Eric A. Ross — 1999
• Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.Diane Savarese, Susan Halabi, Vera Hárs — 2001
• Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.I. F. Tannock, David Osoba, Martin R. Stockler — 1996
• Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancerAlan Yagoda, Daniel Petrylak — 1993
• Phase II evaluation of docetaxel plus one‐day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinomaVictoria J. Sinibaldi, Michael A. Carducci, S. Moore-Cooper — 2002
• Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.Aaron Weitzman, Gary Shelton, Nancy Zuech — 2000
• Mechanisms of action and clinical uses of estramustine.Ralph C. Benson, Beryl Hartley‐Asp — 1990
• Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.Mario A. Eisenberger, Brent A. Blumenstein, E. David Crawford — 1998
• A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.E. David Crawford, Mario A. Eisenberger, David G. McLeod — 1989
• Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines.Willi Kreis, Daniel R. Budman, Anthony Calabro — 1997
• Cancer Statistics, 2004Ahmedin Jemal, Ram C. Tiwari, Thomas S. Murray — 2004
• Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer.Timothy J. McDonnel, Nora M. Navone, Patricia Troncoso — 1997
• Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.William R. Berry, Shaker R. Dakhil, Manuel Modiano — 2002
• Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.Subrata Haldar, Janaki Chintapalli, C M Croce — 1996
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.Ian F. Tannock, Ronald de Wit, William R. Berry — 2004
• Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.D. Scott Ernst, I. F. Tannock, Eric Winquist — 2003
• Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.Glenn J. Bubley, Michael A. Carducci, William L. Dahut — 1999

Cited by

• Sekundäre Hormonablation beim hormonunabhängigen ProstatakarzinomDieter Schilling, Georgios Gakis, Ulf-Wilhelm Bökeler — 2009
• Potassium channels in prostate and colonic cancerJiraporn Ousingsawat — 2007
• Kastrationsrefraktäres Prostatakarzinom (CRPC)Wolfgang Loidl, Ferdinand Luger, Alexander Roosen — 2014
• Recent Progress in the Treatment of Advanced Prostate Cancer With Intermittent Dose-Intense Calcitriol (DN-101).Michael K. Brawer — 2007
• The role of hormonal treatment in prostate cancer.S. H. Flüchter, Ralf Weiser, Christoph Gamper — 2007
• Targeting the prostate tumor microenvironment and vasculature : the role of castration, tumor-associated macrophages and pigment epithelium-derived factorSofia Halin Bergström — 2009
• A retrospective study of the time to clinical endpoints for advanced prostate cancer幹 山本, 顕也 上村, 達 高橋 — 2005
• Present Status and Perspectives in the Treatment of Hormone-Refractory Prostate Cancer何淑霞 — 2005
• Docetaxel for the treatment of prostate cancer.功己 栗崎, 雅邦 石川, 輝之 小川 — 2005
• A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to boneNicola Dal Pozzolo — 2006
• Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.Ursula Kolbe, Jane Smyth — 2006
• The case for early chemotherapy for the treatment of metastatic disease.Evangelos Bampas, Aris Pagourtzis, George Pierrakos — 2006
• Cellular changes in prostate cancer cells induced by intermittent androgen suppression.Teck Kian. Tan — 2007
• Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer?I. Dostrovsky, Z. Fraenkel, P. Rabinowitz — 2007
• The role of Src in prostate cancer.W Fabbri, Giuseppe Mornacchi, Francesco Gagliardi — 2007
• Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patientsDonald G. Reinertsen, Leland Shaeffer — 2007
• Therapeutic integration of c‐myc and bcl‐2 antisense molecules with docetaxel in a preclinical model of hormone‐refractory prostate cancerHatim Α. Omar — 2007
• Positron emission tomography imaging as a cancer biomarkerO.J. Elgert, A.W. Brown — 2007
• Evidence of a novel docetaxel sensitizer, garlic‐derived S‐allylmercaptocysteine, as a treatment option for hormone refractory prostate cancerJuan Sidharta Camara Melo — 2008
• Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.Bernhard Rohrbacher — 2008

Related papers

• Which drug combination for hormone-refractory prostate cancer?Sheila A Doggrell — 2005
• Docetaxel and Estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerPatrick C. Walsh — 2005
• Future directions in the treatment of androgen-independent prostate cancer.Daniel P. Petrylak — 2005
• 159 INVITED Targeting MEK in tumors with BRAF and RAS mutationsDavid B. Solit — 2007
• Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.Stéphane Oudard, Eugéniu Banu, Philippe Beuzeboc — 2005
• Phase II randomised trial of docetaxel (D), estramustine (E) and prednisone (P) — Two schedules — versus mitoxantrone (M) and prednisone in patients (PTS) with hormone refractory prostate cancer (HRPC)S. Qudard, Eugéniu Banu, Éric Voog — 2003
• Chemotherapy for androgen-independent prostate cancerDaniel P. Petrylak — 2005
• Chemotherapy for hormone-resistant prostate cancer: Where are we today?S.J. Harland, Tomáš Büchler — 2007